KLRK1 and Burkitt lymphoma: The combination of anti-CD20 CAR exPBNK cells with a histone deacetylase inhibitor romidepsin, which enhanced expression of NKG2D ligands on the surface of BL, significantly killed BL, reduced tumor burden, and extended the survival in NSG mice xenografted with human BL cells [85].